The Marked Chart Wire · Series of events
Series of events · Hims & Hers
Hims & Hers expands products and faces legal motion
The telehealth company added new treatments and partners while seeking to dismiss a federal lawsuit.
Updated
The flow in 3 points
- 96 percent of users hit normal hormone levels in 90 days
- FTC dismissal arguments scheduled for January 7
- Benefits program now includes 14 partners
What happened, in order
Times are Eastern-
Where it began
Testosterone launch
Hims & Hers introduced new hormone treatments, including shots and pills, noting 96 percent of users reached normal levels in 90 days.
Read the story -
Turning point
FTC dismissal bid
The firm requested a California court dismiss an FTC lawsuit alleging deceptive marketing and data misuse, with arguments set for January 7.
Read the story -
Latest
Partner expansion
Hims & Hers expanded its benefits program to 14 partners by adding Grüns, Medjet, Tonal, and Viome, stating it keeps no margin on discounts.
Read the story
How they connect
The company first launched new testosterone products, then sought to dismiss a regulatory lawsuit, and later expanded its subscriber benefits network.
What to watch
- January 7 court hearing on the FTC motion
The stocks in this series
Prices from Live · updated 9:52 AM ET. Each tile opens the stock's chart and news.
A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.